RenovoRx will present at the iAccess Alpha Best Ideas Winter Investment Conference on December 9, spotlighting early commercial traction for its FDA-cleared RenovoCath drug-delivery catheter and progress in its Phase III TIGeR-PaC trial of intra-arterial gemcitabine in locally advanced pancreatic cancer. The company reported approximately $900,000 in revenue through the first nine months of 2025 from RenovoCath sales, with repeat orders and adoption expanding across new sites, including several National Cancer Institute–designated centers. Alongside the pivotal program, the company is running a real-world registry of RenovoCath use in solid tumors and supporting investigator-initiated studies in borderline resectable and oligometastatic pancreatic cancer.
The immediate story is a small-cap, medtech–oncology hybrid trying to turn a cleared delivery device into a platform while prosecuting a high-stakes, drug–device Phase III under CDER oversight. The strategic question is whether early device revenue and real-world evidence can build a durable market beachhead ahead of efficacy data, or whether the value unlock hinges almost entirely on the TIGeR-PaC readout.
For Commercial leaders, this is a test case in bridging a device-first entry to a combination-product opportunity. RenovoCath can be sold today under its existing clearance for targeted infusion and temporary vessel occlusion, creating procedural use and training pathways with interventional radiologists and surgical oncologists. If the intra-arterial gemcitabine product ultimately succeeds, the company gains orphan exclusivity in pancreatic and bile duct cancers, shifting the conversation from catheter choice to a proprietary therapy enabled by the same hardware. That sequencing could lower launch friction, but only if early adopters translate into durable champions and if purchasing committees see clear clinical and economic value.
Medical Affairs teams will note the reliance on a post-marketing registry and investigator-initiated trials to generate pragmatic evidence on safety, workflow, and patient selection. In a category where prior attempts to improve pancreatic cancer outcomes with loco-regional approaches have struggled, real-world data will be instrumental for payer discussions and clinical guideline influence, especially if they illuminate which patients benefit most from trans-arterial micro-perfusion versus systemic chemotherapy. Education for HCPs will need to span not only interventional technique, but also multidisciplinary coordination across tumor boards, peri-procedural care, and toxicity management.
Payers will scrutinize whether localized delivery offers meaningful improvements in survival or quality of life and whether it reduces systemic toxicity and downstream costs. Reimbursement will hinge on clear coding pathways, site-of-care economics, and comparative effectiveness. Without compelling differentiation, uptake risks being constrained to a handful of high-volume centers where champions drive use; with strong outcomes and operational clarity, the device could scale as a procedural standard while the combination product moves through review.
This development sits at the intersection of several industry currents: the resurgence of interventional oncology, the convergence of medtech and pharma in combination products, the increasing use of capital-efficient investigator studies to de-risk pivotal bets, and the growing expectation that real-world evidence will accompany — not follow — trial data to secure coverage. It also aligns with a broader pattern of small innovators seeking distribution partnerships to accelerate device adoption while preserving optionality for drug-development value.
The next 12 months will reveal whether RenovoRx can translate early commercial signals into a repeatable hospital adoption model and secure a strategic partner to scale, or whether the narrative remains tethered to a single pivotal readout. If TIGeR-PaC demonstrates clinically meaningful benefit, does the market pivot from device curiosity to a protected therapy franchise — and who moves fastest to integrate it into pancreatic cancer care pathways?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
